Prelude Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $592K | Buy |
4,684
+2,901
| +163% | +$382K | 0.04% | 463 |
|
|
2026
Q1 | $248K | Buy |
+1,783
| New | +$250K | 0.02% | 801 |
|
|
2025
Q3 | – | Sell |
-9,264
| Closed | -$1.03M | – | 1244 |
|
|
2025
Q2 | $1.03M | Buy |
9,264
+6,803
| +276% | +$724K | 0.1% | 252 |
|
|
2025
Q1 | $276K | Sell |
2,461
-8,099
| -77% | -$836K | 0.02% | 741 |
|
|
2024
Q4 | $975K | Sell |
10,560
-3,920
| -27% | -$353K | 0.06% | 389 |
|
|
2024
Q3 | $1.21M | Buy |
+14,480
| New | +$1.1M | 0.07% | 332 |
|
|
2022
Q2 | – | Sell |
-5,488
| Closed | -$326K | – | 1896 |
|
|
2022
Q1 | $326K | Sell |
5,488
-12,467
| -69% | -$797K | 0.01% | 1045 |
|
|
2021
Q4 | $1.3M | Buy |
+17,955
| New | +$1.24M | 0.03% | 487 |
|
|
2021
Q2 | – | Sell |
-22,921
| Closed | -$1.48M | – | 1748 |
|
|
2021
Q1 | $1.48M | Buy |
22,921
+14,875
| +185% | +$959K | 0.04% | 442 |
|
|
2020
Q4 | $469K | Buy |
8,046
+1,106
| +16% | +$66.7K | 0.01% | 745 |
|
|
2020
Q3 | $439K | Sell |
6,940
-1,317
| -16% | -$91.3K | 0.02% | 468 |
|
|
2020
Q2 | $635K | Sell |
8,257
-15,779
| -66% | -$1.21M | 0.04% | 419 |
|
|
2020
Q1 | $1.8M | Buy |
24,036
+11,220
| +88% | +$775K | 0.12% | 120 |
|
|
2019
Q4 | $833K | Buy |
+12,816
| New | +$835K | 0.03% | 440 |
|
|
2019
Q3 | – | Sell |
-29,524
| Closed | -$2M | – | 1824 |
|
|
2019
Q2 | $2M | Buy |
29,524
+6,401
| +28% | +$421K | 0.1% | 203 |
|
|
2019
Q1 | $1.5M | Sell |
23,123
-19,436
| -46% | -$1.29M | 0.08% | 244 |
|
|
2018
Q4 | $2.66M | Buy |
42,559
+22,769
| +115% | +$1.59M | 0.18% | 119 |
|
|
2018
Q3 | $1.53M | Sell |
19,790
-2,654
| -12% | -$200K | 0.09% | 254 |
|
|
2018
Q2 | $1.59M | Buy |
22,444
+17,432
| +348% | +$1.23M | 0.1% | 214 |
|
|
2018
Q1 | $378K | Sell |
5,012
-8,002
| -61% | -$636K | 0.03% | 512 |
|
|
2017
Q4 | $932K | Buy |
13,014
+3,648
| +39% | +$277K | 0.07% | 268 |
|
|
2017
Q3 | $759K | Sell |
9,366
-33,437
| -78% | -$2.56M | 0.07% | 286 |
|
|
2017
Q2 | $3.03M | Buy |
42,803
+6,377
| +18% | +$424K | 0.29% | 71 |
|
|
2017
Q1 | $2.47M | Buy |
36,426
+7,650
| +27% | +$538K | 0.24% | 102 |
|
|
2016
Q4 | $2.06M | Buy |
28,776
+2,044
| +8% | +$152K | 0.25% | 113 |
|
|
2016
Q3 | $2.12M | Sell |
26,732
-11,645
| -30% | -$946K | 0.22% | 91 |
|
|
2016
Q2 | $3.2M | Sell |
38,377
-851
| -2% | -$75.5K | 0.45% | 44 |
|
|
2016
Q1 | $3.6M | Buy |
39,228
+547
| +1% | +$49.3K | 0.5% | 25 |
|
|
2015
Q4 | $3.91M | Buy |
38,681
+3,040
| +9% | +$316K | 0.61% | 30 |
|
|
2015
Q3 | $3.5M | Buy |
35,641
+14,956
| +72% | +$1.66M | 0.51% | 36 |
|
|
2015
Q2 | $2.42M | Buy |
20,685
+1,338
| +7% | +$146K | 0.34% | 64 |
|
|
2015
Q1 | $1.9M | Buy |
19,347
+546
| +3% | +$55.4K | 0.26% | 88 |
|
|
2014
Q4 | $1.77M | Sell |
18,801
-6,400
| -25% | -$662K | 0.26% | 70 |
|
|
2014
Q3 | $2.68M | Buy |
25,201
+1,760
| +8% | +$172K | 0.38% | 36 |
|
|
2014
Q2 | $1.94M | Buy |
23,441
+5,670
| +32% | +$441K | 0.26% | 74 |
|
|
2014
Q1 | $1.26M | Sell |
17,771
-1,750
| -9% | -$137K | 0.17% | 137 |
|
|
2013
Q4 | $1.47M | Buy |
19,521
+2,000
| +11% | +$139K | 0.24% | 82 |
|
|
2013
Q3 | $1.1M | Sell |
17,521
-14,193
| -45% | -$848K | 0.18% | 116 |
|
|
2013
Q2 | $1.63M | Buy |
+31,714
| New | +$1.65M | 0.35% | 51 |
|
Other funds holding GILD
Prelude Capital Management's GILD Position: Q2 2026 in Review
Prelude Capital Management increased its Gilead Sciences (GILD) stake by 163% in Q2 2026, buying an estimated $382K and bringing the position to 4,684 shares worth $592K. The position accounts for 0.04% of the portfolio, ranked #463.
Prelude Capital Management first reported a position in GILD in Q2 2013 and has held it in 39 quarters since. The position peaked at $3.91M in Q4 2015. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Prelude Capital Management held 4,684 shares of Gilead Sciences worth $592K as of Q2 2026.
- Prelude Capital Management bought 2,901 Gilead Sciences shares in Q2 2026, an estimated $382K.
- Gilead Sciences made up 0.04% of Prelude Capital Management's portfolio in Q2 2026, its #463 holding.
- Prelude Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 39 quarters since.
- Prelude Capital Management's Gilead Sciences position peaked at $3.91M in Q4 2015.
- 2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.